vedolizumab (Entyvio)

following an abbreviated submission:

vedolizumab (Entyvio®) is accepted for restricted use within NHSScotland

Indication under review: for the treatment of adult patients with moderately to severely active Crohn's disease who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumour necrosis factor-alpha (TNFα) antagonist.

SMC restriction: for the treatment of adult patients with moderately to severely active Crohn's disease who have had an inadequate response with, lost response to, or were intolerant to a TNFα antagonist.

SMC has previously accepted vedolizumab powder for concentrate for solution for intravenous infusion for restricted use in NHSScotland for this indication (SMC1064/15).

This advice applies only in the context of an approved NHSScotland Patient Access Scheme (PAS) arrangement delivering the cost-effectiveness results upon which the decision was based, or a PAS/ list price that is equivalent or lower.